11 February 2021 - Late treatment study
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
et al., J. Infection, doi:10.1016/j.jinf.2021.02.011 (Peer Reviewed)
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
|
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7,192, control 1,361, odds ratio converted to relative risk, univariate, control prevalence approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Lora-Tamayo et al., 2/11/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.